FIRST AMENDMENT TO AMENDED AND RESTATED LETTER AGREEMENTLetter Agreement • April 17th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus
This First Amendment to Amended and Restated Letter Agreement (this “Amendment”), dated as of April 14, 2024, is made by and among Allurion Technologies, Inc. (formerly known as Allurion Technologies Holdings, Inc.), a Delaware corporation (the “Company”), Allurion Technologies, LLC (formerly known as Compute Health LLC), a Delaware limited liability company (“Opco”), RTW Master Fund, Ltd., an Exempted Company incorporated in the Cayman Islands with limited liability (“RTW Master”), RTW Innovation Master Fund, Ltd., an Exempted Company incorporated in the Cayman Islands with limited liability (“RTW Innovation”), RTW Biotech Opportunities Operating Ltd, an investment company limited by shares incorporated under the laws of Guernsey (“RTW Biotech Operating”), 4010 Royalty Investments ICAV, an Irish collective asset-management vehicle, for and on behalf of its sub‑fund, 4010 Royalty Investments Fund 1 (the “4010 ICAV”), and 4010 Royalty Master Fund, LP, a Cayman Islands limited partnershi
OMNIBUS AMENDMENTRevenue Interest Financing Agreement • April 17th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
This Omnibus Amendment (this “Amendment”), dated as of April 14, 2024, is among 4010 Royalty Investments ICAV, an Irish collective asset-management vehicle, for and on behalf of its sub-fund, 4010 Royalty Investments Fund 1, and 4010 Royalty Master Fund, LP, a Cayman Islands limited partnership (each and collectively, together with its and their successors and permitted assigns, the “Investor”), Allurion Technologies, LLC, a Delaware limited liability company (the “Company”), Allurion Technologies, Inc., a Delaware corporation (formerly known as Allurion Technologies Holdings, Inc.) (“Parent”), Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia (“Allurion Australia”), and RTW Investments, LP, as agent for the Investor (in such capacity, together with its successors and permitted assigns, the “Agent”). Each of the Company, Parent, Allurion Australia, the Investor and the Agent is referred to in this Amendment as a “Party” and collectively as
FIRST AMENDMENT TO NOTE PURCHASE AGREEMENTNote Purchase Agreement • April 17th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus
This First Amendment to Note Purchase Agreement (this “Amendment”), dated as of April 16, 2024, is among Allurion Technologies, Inc., a Delaware corporation (formerly known as Allurion Technologies Holdings, Inc.) (together with its successors and permitted assigns, the “Company”), the purchasers party to the Existing Note Purchase Agreement (as defined below) (each, a “Purchaser” and, collectively, the “Purchasers”), RTW Investments, LP, as agent for the Purchasers (in such capacity, together with its successors and permitted assigns, the “Principal Purchaser”), and Acquiom Agency Services LLC, as collateral agent for the Purchasers and the Principal Purchaser (in such capacity, together with its successors and permitted assigns, the “Collateral Agent”). Each of the Company, the Purchasers, the Principal Purchaser and the Collateral Agent is referred to in this Amendment as a “Party” and collectively as the “Parties”. Capitalized terms used herein and not otherwise defined shall have
NOTE PURCHASE AGREEMENTNote Purchase Agreement • April 17th, 2024 • Allurion Technologies, Inc. • Surgical & medical instruments & apparatus • New York
This Note Purchase Agreement (this “Agreement”) is entered into as of April 14, 2024 (the “Execution Date”) by and among Allurion Technologies, Inc., a Delaware corporation (formerly known as Allurion Technologies Holdings, Inc.) (together with its successors and permitted assigns, the “Company”), the purchasers from time to time party hereto (each, a “Purchaser” and, collectively, the “Purchasers”), RTW Investments, LP, as agent for the Purchasers (in such capacity, together with its successors and permitted assigns, the “Principal Purchaser”) and Acquiom Agency Services LLC, as collateral agent for the Purchasers and the Principal Purchaser (in such capacity, together with its successors and permitted assigns, the “Collateral Agent”).
